The following article is part of our coverage of the American Academy of Dermatology’s annual meeting (AAD 2021) that is being held virtually from April 23-25, 2021. Dermatology Advisor‘s staff will report on the top research in dermatologic advances and clinical care. Check back for the latest news from AAD 2021.
Repeated use of daxibotulinumtoxinA for injection (DAXI), an investigational botulinum toxin type A formulation, led to noticeable and progressive improvements in static glabellar lines (GL), according to study results presented at the American Academy of Dermatology’s Virtual Meeting Experience (AAD VMX) 2021, held online from April 23 to April 25, 2021.
This analysis of the phase 3 SAKURA trials included 568 patients (mean age, 50.7 years) with moderate or severe dynamic GL who were treated with 40 U DAXI. Patients received DAXI for 36 weeks in the SAKURA 1 and 2 trials, while SAKURA 3 was an open-label safety trial lasting 84 weeks.
The investigators of this pooled analysis examined GL severity at maximum frown and at rest, as measured with validated 4-point rating scales. Retreatment with DAXI was allowed as a participant’s GL severity returned to levels similarly reported at baseline.
Nearly half (48.8%) of the participants had mild GL severity at baseline, based on the Investigator Global Assessment-Frown Wrinkle Severity scale. Approximately 46.3% and 35.6% of participants had mild and moderate static GL severity, respectively.
By 4 weeks of the first DAXI treatment, up to 57.9% of participants perceived no static GL. The percentage of participants reporting no static GL increased to 68.7% at week 4 of the second DAXI treatment and 71.5% at week 4 of the third treatment.
Similar investigator-assessed improvements were observed in static GL. Overall, 20% to 42% of participants who had severe static GL at baseline also achieved no static GL by 4 weeks of the third cycle of DAXI treatment.
According to the investigators, DAXI’s extended therapeutic benefit in dynamic GL offers a likewise “longer window of muscle hypoactivity, permitting an extended period for dermal remodeling to occur.” Ultimately, the investigators added, this may possibly account for the observed progressive improvements in static GL with repeated treatments of DAXI.
Disclosure: This clinical trial was supported by Revance Therapeutics. Please see the original reference for a full list of authors’ disclosures.
Visit Dermatology Advisor‘s conference section for more coverage from AAD 2021.
Glogau R, Kontis T, Liu Y, Gallagher CJ. DaxibotulinumtoxinA for injection (DAXI)-treated subjects show progressive improvement in static glabellar lines with repeated treatment. Poster presented at: American Academy of Dermatology’s Virtual Meeting Experience (AAD VMX) 2021; April 23-25, 2021. Poster 26550.